share_log

HC Wainwright & Co. Reiterates Neutral on CytomX Therapeuticsto Neutral

Benzinga ·  Jan 7 19:32

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Neutral.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment